Form 4: Jarry Olivier Roger reports acquisition/exercise transactions in OSTX

Rhea-AI Filing Summary

Jarry Olivier Roger reported acquisition or exercise transactions in a Form 4 filing for OSTX. The filing lists transactions totaling 50,000 shares. Following the reported transactions, holdings were 50,000 shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jarry Olivier Roger

(Last) (First) (Middle)

C/O OS THERAPIES INCORPORATED

115 PULLMAN CROSSING ROAD, SUITE 103

(Street)

GRASONVILLE MD 21638

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
OS Therapies Inc [ OSTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock options (right to buy)	$1.34	01/22/2026		A		50,000		(1)	01/22/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. On January 22, 2026, the reporting person was granted options to purchase 50,000 shares of the issuer's common stock pursuant to the terms and conditions of a stock option award agreement. These options vest in full on the one-year anniversary of the date of grant, provided that the reporting person is serving as a director of the issuer on such date.

	/s/ Olivier Jarry	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did OS Therapies Inc (OSTX) report for Olivier Jarry?

OS Therapies Inc reported that director Olivier Jarry received a grant of 50,000 stock options on January 22, 2026. Each option gives him the right to buy one share of common stock at a $1.34 exercise price, subject to vesting conditions.

How many OS Therapies Inc (OSTX) options were granted to director Olivier Jarry?

Director Olivier Jarry was granted 50,000 stock options of OS Therapies Inc. Each option is a right to purchase one share of common stock, bringing his directly held derivative securities balance to 50,000 options after the reported transaction.

What is the exercise price of the new OSTX stock options granted to Olivier Jarry?

The newly granted OS Therapies Inc stock options to director Olivier Jarry have an exercise price of $1.34 per share. This is the price he must pay to purchase each underlying share when exercising the options after they vest.

When do Olivier Jarry’s OS Therapies Inc (OSTX) stock options vest?

The 50,000 OS Therapies Inc stock options granted to Olivier Jarry vest in full on the one-year anniversary of the January 22, 2026 grant date. Vesting requires that he continues serving as a director on that one-year anniversary.

Is Olivier Jarry’s ownership of OS Therapies Inc (OSTX) options direct or indirect?

Olivier Jarry’s ownership of the reported 50,000 OS Therapies Inc stock options is direct. The filing lists his ownership form as “D” for direct, with no indication of trusts, entities, or indirect beneficial ownership in the accompanying footnotes.

What type of transaction code was used for Olivier Jarry’s OSTX option grant?

The transaction used code “A,” which indicates a grant, award, or other acquisition of derivative securities. This confirms that Olivier Jarry received the 50,000 OS Therapies Inc stock options as a compensatory award rather than through an open-market purchase or sale.